BELVIQ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:
- 30 kg/m² or greater (obese), or
- 27 kg/m² or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)
DOSAGE AND ADMINISTRATION
The recommended dose of BELVIQ is 10 mg administered orally twice daily. Do not exceed recommended dose.
BELVIQ can be taken with or without food.
Response to therapy should be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, discontinue BELVIQ, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment
The following important adverse reactions are described below and elsewhere in labeling:
- Serotonin Syndrome or NMS-like Reactions
- Valvular Heart Disease
- Cognitive Impairment
- Psychiatric Disorders
- Heart Rate Decreases
- Hematological Changes
- Prolactin Elevation